Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Incyte finally has some good news to share about one drug it’s discovered that’s not Jakafi — albeit one that doesn’t belong to it anymore. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
